We found that both the h‐mIL‐6R mAb and Tocilizumab (IL‐6R blockades) significantly reduced elevation of pro‐inflammatory cytokines, alleviated organ injury and improved mortality in the LPS‐induced SIRS model. This evidence concerns the gene IL6R and systemic inflammatory response syndrome.